Blood biomarker monitoring to detect early stomach pre-cancer and cancer risk
Official title: Identification of Biomarkers of Risk for Pre-neoplastic and Neoplastic Lesions for the Development of Gastric Cancer
Run by Centro di Riferimento Oncologico - Aviano · NCT07374731 · Data updated 2026-11-12
This project will test whether regular fasting blood tests measuring pepsinogen and G17 gastrin can help identify adults at higher risk of stomach atrophy or cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 192 (estimated) |
| Sponsor | Centro di Riferimento Oncologico - Aviano Academic / other |
| Locations | 1 site (Aviano, Pordenone) |
| Status | Recruiting |
| Started | May 21, 2025 |
| Main results expected | January 31, 2027 |
| Study ends | January 31, 2027 |
| Registry record updated | February 2, 2026 |
| Trial ID | NCT07374731 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) who are fasting and request pepsinogen testing or gastroscopy, have suspected pre-neoplastic gastric lesions, or have gastric cancer before treatment and can give informed consent.
✕Probably not a fit
People under 18, pregnant women, patients with another malignancy within the past five years, or those unable to consent are excluded and therefore unlikely to receive benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational program tracks circulating biomarkers—pepsinogen and G17 gastrin—in fasting adults who request pepsinogen testing, undergo gastroscopy, or have untreated gastric cancer. Participants provide serum samples for biomarker analysis and clinical/endoscopic data are linked when available to give context to marker changes. Biomarker levels are followed over time to detect worsening trends, and clinicians are alerted if values deteriorate. The goal is to offer dynamic, preventive surveillance to prompt timely diagnostic or therapeutic follow-up rather than to deliver an experimental treatment.
Why it matters
Potential benefit: If successful, this monitoring could enable earlier detection of gastric atrophy or cancer and prompt timely follow-up that may improve outcomes.
How similar studies have gone: Previous studies have shown that pepsinogen and gastrin levels correlate with gastric atrophy and increased cancer risk, but routine longitudinal circulating biomarker monitoring as a preventive alert system is relatively under-tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged over 18; * Ability to understand, accept, and sign the informed consent form for the study; * Ability to understand, accept, and sign the consent form for data processing; * Ability to understand, accept, and sign the consent form for the collection of a serum sample for research purposes; * Patients who are fasting and have requested a pepsinogen test or gastroscopy, or who have gastric cancer prior to treatment; * Subjects who are fasting and have suspected pre-neoplastic/neoplastic gastric lesions or who have requested a pepsinogen test and for whom endoscopic examination data are available. Exclusion Criteria: * Patients under the age of 18 * Pregnant women * Patients with a coexisting or previous diagnosis of another malignant neoplasm in the last 5 years * Patients unable to understand, accept, and sign the consent form for data processing
Where it's running
-
Centro di Riferimento Oncologico (CRO) di aviano-IRCCS
Aviano, Pordenone, Italy Recruiting
Study contacts
- Principal investigator: Valli De Re — Centro di Riferimento Oncologico
- Study coordinator: Valli De Re, PhD
- Email: vdere@cro.it
- Phone: +39 0434 659672
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.